不同化疗药物分别与奥沙利铂联用对胃癌术后复发转移患者生存质量及血清相关肿瘤指标的影响  

Influence of different chemotherapeutic drugs combined with oxaliplatin on living quality and serum related tumor markers in gastric cancer patients with postoperative recurrence and metastasis

作　　者：王怡 顾康生[1] 王保龙[3] Wang Yi Gu Kangsheng Wang Baolong(Department of Oncology, First Affiliated Hospital of Anhui Medical University ,Wuhu ,Anhui 230022, China First Department of Oncology , Tongling Municipal Peoplets Hospital, Tongling ,Anhui 244000, China Department of Oncology ,Affiliated Provincial Hospital ,Anhui Medical University ,Wuhu ,Anhui 230022 ,China)

机构地区：[1]安徽医科大学第一附属医院肿瘤科,合肥230022 [2]安徽省铜陵市人民医院肿瘤一科,244000 [3]安徽医科大学附属省立医院肿瘤科,合肥230022

出　　处：《重庆医学》2017年第27期3795-3797,共3页Chongqing medicine

基　　金：国家自然科学基金资助项目(81172172)

摘　　要：目的研究卡培他滨和替吉奥分别与奥沙利铂联用对胃癌术后复发转移患者生存质量及血清相关肿瘤指标的影响。方法选择2013年1月至2015年12月在安徽省铜陵市人民医院接受治疗的胃癌术后复发转移患者106例。用随机数字表法分为对照组和观察组,每组各53例,对照组患者给予替吉奥联合奥沙利铂治疗,观察组患者给予卡培他滨联合奥沙利铂治疗。比较两组患者的临床疗效、生活质量、血清相关肿瘤指标和不良反应。结果对照组患者的有效率为64.15%,观察组患者的有效率为69.81%,差异无统计学意义(P>0.05)。对照组患者生活质量改善率为73.58%,稳定率为18.87%,下降率为26.42%,总改善率为73.58%,观察组分别为49.06%、20.75%、30.19%和69.81%,差异无统计学意义(P>0.05)。治疗后两组患者的糖类抗原(CA)50、CA125、CA199及癌胚抗原(CEA)水平较治疗前均明显下降(P<0.05),但是两组患者的血清相关肿瘤指标比较差异无统计学意义(P>0.05)。两组患者常见的不良反应包括血红蛋白下降、白细胞下降、血小板减少和恶心呕吐,两组患者均可耐受,差异无统计学意义(P>0.05)。结论卡培他滨或替吉奥与奥沙利铂联用治疗胃癌术后复发转移的疗效相当,患者的生活质量及血清相关肿瘤指标改善情况相当,不良反应均可耐受。Objective To study the influence of capecitabine or S-1 combined with oxaliplatin on the quality of life and serum tumor marker in gastric cancer patients with postoperative recurrence and metastasis. Methods One hundred and six cases of post- operative recurrence and metastasis treated by gastric cancer radical operation m our hospital from January 2013 to December 2015 were selected and divided into the control group and observation group according to the random number table method, 53 cases in each group. The control group was given S-1 combined with oxaliplatin treatment,while the experimental group was given capecitabine combined with oxaliplatin treatment. The clinical efficacy, quality of life, serum related tumor markers and adverse reactions were compared between the two groups. Results The effective rate was 64. 15% in the control group and 69.81% in the observation group,the difference was not statistically significant （P〈0.05）. The improvement rate of the quality of life in the control group was 73.58% ,the stability rate was 18.87% and decline rate was 26.42% ,the total improvement rate was 73.58% ,which in the observation group were 49.06 %, 20. 75 %, 30.19 % and 69.81% respectively, the differences were not statistically significant （P〉0.05）. After treatment,the levels of CA50,CA125 ,CA199 and CEA in the two groups were significantly decreased compared with before treatment （P〈0.05）, but the serum related tumor markers had no statistically significant difference between the two groups （P〉0.05）. The common adverse reactions in the two groups included hemoglobin decrease, white blood cell decline, thrombocytopenia, nausea and vomiting, the two groups could be tolerated, the difference was not statistically significant （P〉0.05）. Conclusion Capecitabine or S-1 combined with oxaliplatin has the same curative effect in treating postoperative recurrence and metastasis after gastric cancer operation, the improvement of quality of life and serum related tumor indicators is si

关 键 词：胃肿瘤 卡培他滨 替吉奥 奥沙利铂 生存质量 

分 类 号：R735.2[医药卫生—肿瘤]